Menopause
AI identifies subjective cognitive decline during menopause transition
Machine learning models can more quickly and affordably identify women with severe subjective cognitive decline during the menopause transition, effectively opening the door to better management of cognitive health, a new study suggests.
Subjective cognitive decline refers to a person’s perceived decline in memory or other cognitive functions. Cognitive decline, one of the more common symptoms related to the menopause transition, is especially concerning, because it not only affects a woman’s quality of life but can also indicate a higher risk of severe neurodegenerative diseases, such as Alzheimer disease.
Previous evidence suggests a number of risk factors for cognitive decline, including aging, hypertension, obesity, and depression, among others. A challenge is that most current models for cognitive health are centered around dementia, an incurable disease that offers limited opportunities for clinical intervention.
Although subjective cognitive decline does not always predict long-term cognitive changes or dementia, a predictive model for cognitive decline and related factors could allow for early intervention to protect cognitive health.
Existing testing for cognitive performance is largely based on models typically incorporating various laboratory indicators such as blood glucose, blood lipids, and brain imaging.
The complexity and high cost of these models often make them impractical to implement in a clinical setting. In comparison, questionnaire-based models offer a simpler and more cost-effective alternative.
These models rely on a number of independent variables, including sociodemographic, work-related, menstrual-related, lifestyle-related, and mental health-related factors.
Machine learning has shown tremendous potential in the field of cognitive health in recent years. By mining patterns and trends from large datasets, it can construct accurate, reliable models and automate the handling of complex variable relationships.
In this latest study involving more than 1,200 women undergoing the menopause transition, researchers were able to develop and validate a machine learning model for identifying women experiencing severe subjective cognitive decline, along with associated factors.
These findings provide a novel guidance for interventions designed to preserve cognitive health in women undergoing the menopause transition. Additional research is needed to validate these results and identify additional potential influencing factors.
“This study highlights how the use of machine learning can be employed to identify women experiencing severe subjective cognitive decline during the menopause transition and potential associated factors. Early identification of high-risk persons may allow for targeted interventions to protect cognitive health. Future studies involving objective measures of cognition and longitudinal follow-up are crucial to better understanding these associations,” said Dr. Stephanie Faubion, medical director for The Menopause Society.
Digital diagnostics company Medichecks has acquired specialist menopause health platform and clinic My Menopause Centre.
The deal is part of Medichecks’ move into clinical services and follows its earlier purchase of Leger Clinic, creating what the company describes as a hormone health offering for women and men across the UK.
Medichecks and My Menopause Centre will combine digital services with clinical governance. The acquisition aims to enhance Medichecks’ ability to deliver integrated testing, diagnosis and ongoing clinical support.
The combined group plans to grow its specialist hormone health services, supporting patients across the UK with clinical care throughout different stages of their hormone health journey.
Helen Marsden, co-founder of Medichecks, said: “At Medichecks, our mission is to make healthcare more accessible, evidence-based and patient-centred.
“Helen and Clare have built an outstanding, clinically credible platform that is transforming menopause care for women across the UK.
“Medichecks now owns two CQC Outstanding-rated clinics, the only clinics in their respective sectors to achieve this rating, and we are deeply committed to delivering safe, compassionate and patient-centric care.
“We’re proud to continue the founders’ legacy while supporting the next stage of growth, ensuring more women can access high-quality menopause care when they need it most.”
The CQC, or Care Quality Commission, is the independent regulator of health and social care in England.
The acquisition supports Medichecks’ plans to make hormone healthcare more accessible by delivering integrated testing, diagnosis and ongoing clinical support for patients across the UK.
Helen Normoyle, co-founder and chief executive of My Menopause Centre, said: “We set out to build something resilient, clinically credible and scalable, not just fast.
“Our mission has always been to make menopause care compassionate, accessible and grounded in evidence. Medichecks shares that vision.
“Their digital platform, commitment to clinical excellence and patient-centred care make them the ideal partner to take My Menopause Centre into its next chapter.
“This milestone reflects not only a strong product, but a remarkable team and community.
“I’m deeply proud of what we’ve built and excited to see My Menopause Centre grow further under Medichecks’ leadership.”
Menopause specialist Dr Mary Claire Haver has been appointed as the first chief agewell officer at virtual care clinic Midi Health.
In the role, Dr Haver will work with Midi’s clinical team to develop the AgeWell platform, described as a proactive health model that integrates perimenopause and menopausal care with metabolic health, bone density, brain health and cardiovascular risk assessment.
The platform aims to provide preventative care targeting what the company describes as the primary drivers of female mortality and disability: heart disease, bone loss and cognitive decline.
Joanna Strober, chief executive and co-founder of Midi Health, said: “Longevity care has historically ignored women’s biology, especially during the critical windows of midlife and menopause.
“At Midi Health, we are committed to extending healthspan, not just lifespan, and making that care accessible to millions of women as a core pillar of their health.
“By collaborating with Dr Haver, we are ensuring women continue to have access to care designed for their bodies, their hormones, and their real lives.”
Dr Haver is board-certified in obstetrics and gynaecology, a Menopause Society certified practitioner, a certified culinary medicine specialist and an adjunct associate professor of obstetrics and gynaecology at The University of Texas Medical Branch.
After a career in academic medicine, Dr Haver founded The Pause Life, described as a science and education-based resource for women navigating perimenopause and the menopause transition.
Through her books, unPaused podcast and digital platform, she has provided education on midlife health.
Dr Mary Claire Haver said: “I have spent my career advocating for women to receive the science-backed, no-nonsense guidance they deserve.
“I chose to partner with Midi Health because they are the only platform with the scale and medical rigour to deliver the kind of care women deserve, regardless of their zip codes.
“Together, we are setting a new standard for proactive, preventative care that meaningfully extends both lifespan and healthspan for women.”
Mira has integrated with Oura, letting users see sleep, readiness and temperature trends alongside hormone readings in the Mira app.
The integration lets Mira users view Oura sleep, readiness and temperature trends next to hormone data to show how hormonal shifts affect daily wellbeing. Oura members must consent to share their data with Mira.
Oura is a smart ring that tracks sleep patterns, heart rate and body temperature.
Sylvia Kang, chief executive and founder of Mira. said: “Hormones affect nearly every system in the body, yet are rarely measured or contextualised with daily health signals.
“By bringing these data streams together in one app, Mira and Oura help women move beyond isolated metrics to understand patterns.
“By connecting hormone data with daily health signals, we’re giving women insights they can act on, whether managing fertility, navigating perimenopause, or addressing hormonal imbalances.”
The integration supports several health journeys.
In perimenopause and menopause, users can track temperature and sleep with hormone changes to spot disruptions and improve rest.
For fertility and menstrual cycle awareness, combining hormone data with temperature and wellness signals can help confirm ovulation and clarify cycle patterns.
Users can also link fatigue or poor sleep with hormonal shifts to inform clinical discussions.
Dr Chris Curry is clinical director of women’s health at Oura.
Curry said: “Hormonal changes play a critical role in how women feel each day and are a through line that connects so many aspects of health, from first periods, to menstrual cycles, pregnancy, perimenopause and beyond.
“By combining Mira’s lab-grade hormone data with Oura’s continuous biometrics, we’re helping women see how hormonal shifts show up in their everyday lives.
“This integrated view supports our goal of always supporting body literacy.”
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health7 days agoUS startup builds wearable hormone tracker
-
Wellness3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now